ClinicalTrials.gg

Program

trospium chloride

Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.

Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Furthest: phase 4, since Oct 13, 202515 company-led studies, 7 open or runningNext primary completion: Dec 3, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb97 open or runningphase 4since Oct 13, 2025Jul 6, 2016Dec 3, 2026phase 1 · NCT07204418
AbbVie50 open or runningphase 4since Mar 16, 2009Mar 16, 2009none ahead
Keenova Therapeutics10 open or runningphase 2since Apr 24, 2007Apr 24, 2007none ahead

Also a collaborator on its studies: Alkermes.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2007First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveNew to Keenova TherapeuticsKeenova Therapeutics · NCT00465959 · 24 enrolled · United States
  2. Mar 16, 2009AbbVie's first study: phase 4 study in Urinary Bladder, OveractiveNew to AbbVieAbbVie · NCT00863551 · 12 enrolled · United States
  3. Jul 1, 2009Phase 4 study in ObesityAbbVie · NCT00932022 · 127 enrolled · United States
  4. Sep 16, 2009Phase 1 study in HealthyAbbVie · NCT00986401 · 44 enrolled · United States
  5. Mar 17, 2010Phase 4 study in Urinary Bladder, OveractiveAbbVie · NCT01089751 · 322 enrolled · United States
  6. Aug 9, 2010Phase 4 study in Urinary Bladder, OveractiveAbbVie · NCT01178827 · 20 enrolled · United States
  7. Jul 6, 2016Bristol-Myers Squibb's first study: phase 1 study in SchizophreniaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02831231 · 70 enrolled · United States
  8. Jun 2, 20252 phase 3 studies in Alzheimer DiseaseBristol-Myers Squibb · NCT07011745, NCT07011732
  9. Jun 23, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07063342 · 236 planned · United Kingdom
  10. Aug 21, 2025Phase 3 study in ManiaBristol-Myers Squibb · NCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
  11. Sep 24, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07204418 · 56 planned · United States
  12. Oct 13, 2025Phase 4 study in SchizophreniaBristol-Myers Squibb · NCT07221877 · 60 planned · United States
  13. Nov 21, 2025Phase 4 study in Healthy VolunteersBristol-Myers Squibb · NCT07257120 · 10 enrolled · United States
  14. Jun 30, 2026Phase 3 study in SchizophreniaBristol-Myers Squibb · NCT07686263 · 472 planned · United States, Argentina, Bulgaria and more

Ahead

  1. Dec 3, 2026Primary completion: phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07204418
  2. Mar 29, 2027Primary completion: phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07063342
  3. Jun 28, 2027Primary completion: phase 3 study in ManiaBristol-Myers Squibb · NCT07140913
  4. Dec 30, 2027Primary completion: phase 4 study in SchizophreniaBristol-Myers Squibb · NCT07221877

TargetBeta

CHRM2 →CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospiumruleBristol-Myers Squibbphase 421
AtropineruleLaboratorios Sophia S.A de C.V.phase 317

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more3RecruitingBristol-Myers SquibbMar 3, 2029472
NCT07257120Healthy Volunteers · United States4CompletedBristol-Myers SquibbJun 8, 202610
NCT07221877Schizophrenia · United States4RecruitingBristol-Myers SquibbDec 30, 202760
NCT07204418Healthy Volunteers · United States1RecruitingBristol-Myers SquibbDec 3, 202656
NCT07140913Mania · United States, Argentina, Bulgaria and more3RecruitingBristol-Myers SquibbJun 28, 2027424
NCT07063342Healthy Volunteers · United Kingdom1RecruitingBristol-Myers SquibbMar 29, 2027236
NCT07011745Alzheimer Disease · United States, Argentina, Chile and more3RecruitingBristol-Myers SquibbNov 3, 2028426
NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more3RecruitingBristol-Myers SquibbNov 24, 2028426
NCT02831231Schizophrenia · United States1CompletedBristol-Myers SquibbOct 28, 201670
NCT01178827Urinary Bladder, Overactive · United States4CompletedAbbVieMar 201120
NCT01089751Urinary Bladder, Overactive · United States4CompletedAbbVieJun 2012322
NCT00986401Healthy · United States1CompletedAbbVieNov 200944
NCT00932022Obesity · United States4CompletedAbbVieDec 2011127
NCT00863551Urinary Bladder, Overactive · United States4CompletedAbbVieAug 200912
NCT00465959Pulmonary Disease, Chronic Obstructive · United States2CompletedKeenova TherapeuticsJun 200724

How it is read

Names in the registry

  • “Xanomeline/trospium chloride”, 2 entries
  • “Xanomeline/Trospium Chloride Capsule”, 2 entries
  • “Xanomeline/Trospium Chloride”, 2 entries
  • “Trospium Chloride”, 2 entries
  • “trospium chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.